BACKGROUND: The aim of the study was to achieve an effective target dose in the thyroid by increasing the effective half-life 
Original
The disadvantage of excessively high radioiodine administered activities is that the whole body may be exposed to unnecessary additional radiation. With lower radioiodine doses there is a risk of treatment failure [8] . To minimize such effects it is necessary to increase the effective half-life and decrease the therapeutic dose I uptake and long Teff in the thyroid. An adjunct medication for prolongation of the effective half-life is lithium [11, 12] and non-radioactive iodine ( 127 I). Lithium is not suitable for routine use because of potential side effects and the narrow therapeutic range.
The effective half-life depends on the iodine supply as well as on T24
and T48 radioiodine thyroid uptake [13] [14] [15] and can be prolonged by raising the alimentary iodine supply. Intake of 600 μg of inactive iodide orally may increase the levels of iodine in the intra-thyroidal pool, making more inactive iodine available for hormone synthesis.
In consequence, the radioiodine turnover, hormone biosynthesis, and release of 131 I from thyroid should decrease, all of which lead to prolongation of the effective 131 I half-life during radioiodine therapy [14] .
The aim of the study was to achieve an effective target dose in the thyroid by increasing the effective 
Material and methods
The study was carried out in two groups of patients treated with 131 I: Group A and Group B Group A consisted of 41 patients (32 female and 9 male) with hyperthyroidism. There were 14 patients with Graves' disease and 27 patients with toxic nodular goitre. Mean age was 57. 6 ± 16.9 years. In all patients the effective half-life was less than 3 days and ranged between 1.5 and 2.9 days. Group B consisted of 14 patients (10 female and 4 male), 8 of them with GD, 6 with TNG. Mean age was 55.8 ± 12.9 years. In all patients the effective half-life was less than 3 days and ranged between 1.4 and 2.8 days.
Anti-thyroid drugs were used in patients with overt hyperthyroidism to achieve euthyroidism in those with GD and subclinical hyperthyroidism in those with TNG. ATDs were discontinued five days before 131 I treatment. None of the patients had recently taken any medication known to affect thyroid function or RAIU.
Patients had not received iodine-containing agents in the last six months. Ophthalmological examination of GD patients excluded the presence of active Graves' ophthalmopathy. In a fasting state all patients underwent a RAIU using 2 megabecquerels (MBq) of 131 I. Thyroid 131 I uptake at 24 and 48 hours was carried out and the results used to calculate diagnostic effective half-life (T eff D) (using semi logarithmic paper).
The therapeutic activities of 131 I (A in MBq) were calculated using Marinelli's formula [16] :
Weight of target thyroid tissue (g) × × absorbed dose (Gy) × 24.94 Maximum uptake (%) at time 0 [Tmax] × × effective half-life (days)
Two days after In the studied groups, we evaluated:
-thyroid hormones, fT 4 , and fT 3 serum levels -using radioimmuno assays kits;
-TSH serum levels -by means of immunoradiometric assay kits.
All these parameters were measured before therapy, after 2 weeks, one month, and monthly, up to 12 months after radioiodine therapy. Thyroid scan and ultrasonography were performed after 6 and 12 months to assess the influence of RIT on the size of the thyroid nodules and the volume of the thyroid gland.
Statistical analysis using Student's paired and unpaired t-test was performed.
The protocol of the study was approved by the medical ethical committee of the Medical University of Bialystok, and written informed consent was obtained from all participants. The average duration of follow-up was 12 months.
Results
The results of thyroid RAIU after ingestion of 127 I showed a significant increase in the Teff T as a result of the decrease in the radioiodine turnover in the thyroid gland. Typical changes in decay curves are seen in figure 1. The lowest effective half-life (1.5 days) mean of 2.8 ± 0.69 days was observed in patients with GD before the RIT. After the 127 I administration in all patients there was a significant increase in Teff T (5 days on average) resulting in 28% and 37% increases in the energy target dose in patients with Graves' disease and patients with TNG, respectively. The value of T24 was 51.9 ± 13.2% in the whole group; 51.9 ± 13.2% in group A and 53.2 ± 10.2% in group B. T48 value was 39.8 ± 11.6% in group A and 43. 9 ± 9.3% in group B. Examples of characteristic thyroid scan of patients with TNG and GD, before and after RIT with adjunct use of 127 I, are shown in Figure 4 .
The average concentrations of fT4 and fT3 were, in general, higher in Group A than in Group B. The observed differences were statistically significant in both parameters. In group A we observed a decrease in serum concentrations of fT 3 in both GD and TNG patients, after 2, 5, and 6 months of radioiodine therapy in com- In group A, four (28%) out of 14 patients with GD, required oral l-thyroxin replacement therapy because of hypothyroidism, seven patients (50%) achieved euthyroidism, two patients were in sub- In Group B, all the patients had radioiodine treatment failure and required further radioiodine therapy.
Discussion
Iodine obtained from food is absorbed in the digestive tract as iodide (I -). Once in the blood stream, it diffuses rapidly into the extracellular space then it follows two principal, competitive pathways: uptake by the thyroid gland or excretion in urine. In fasting subjects, radioactive tracer is observed in the neck approximately three minutes after oral administration of 131 I [17] . Absorption is complete in almost all subjects within a maximum of two hours after ingestion. After a single ingestion of radioiodine, thyroid uptake begins rapidly and then reaches a plateau at 10% to 40% of the total iodine ingested in 24 to 48 hours in euthyroid subjects [18] . Uptake varies proportionally to thyroid clearance and plasma iodide concentration. Thyroid clearance depends on the volume and function of the gland. It is adaptive and depends on plasma iodide concentration and dietary intake. As a result, when dietary iodine intake is low, thyroid uptake increases [19, 20] . During exposure to radioactive iodine, the thyroid absorbed dose increases proportionally. Thyroid uptake is higher in adolescents than adults and decreases progressively with age [21] .
A normally functioning thyroid produces 100 μg levothyroxine and 10 μg tri-iodothyronine daily, and the intra-thyroidal turnover of iodine is estimated at 71.15 μg iodine/d.
The study of patients with low effective half-life to benefit from non-radioactive iodide tablets was based on experimental and clinical data [14, 22] . A low iodine diet is thought to be helpful in preparing patients for radioiodine therapy [23, 24] . The effects of inactive iodide after radioiodine therapy or radioiodine exposure are well known. In a retrospective study, Hao et al. [25] described 298 patients who had received 250 mg iodide daily, beginning five days after therapeutic 131 I administration. Serum levothyroxine levels and the intra-thyroid 131 I washout were lower than in patients not receiving additional iodine.
In the treatment of hyperthyroidism, the goal should be to minimize the amount of radiation exposed to the patients and to the environment, while eliminating the hyperthyroid state. Thyroid optimal target energy dose can be achieved by a high uptake and long effective half-life of radioiodine in the thyroid.
In the average patient, the effective half-life is often considered to be five days, which corresponds to a biological half-life of 13.2 days. Radiation dose depends not only on uptake but also on the effective half-life. For a given uptake, the longer the effective half-life, the less radioactive iodine is required to achieve a given radiation dose. Because the radiation dose to the thyroid The administered activity of radioiodine was lower in patients who received inactive iodide (Group A) compared to Group B patients. This method was effective, and euthyroidism was achieved in most cases, but subclinical hyperthyroidism was observed only in 9% of cases. It is worth emphasising that in our study after 12 months of radioiodine therapy only 12% of patients were in hypothyroidism, which is in contrast to the 100% noted in other studies [26] .
In Group B, despite the high doses of radioiodine administered, the failure rate was higher and hyperthyroidism persisted in all the patients. These unsatisfactory results were due to the low Therefore, the effects of ATDs were considerably limited in our study.
According to the results of several studies [29, 30] , thyroid uptake can be blocked (at least 95%) by large doses of potassium iodide (> 100 mg) administered before, and 5 hours after, the radioiodine intake. The administration of 127 I prior to radioiodine therapy is contraindicated because it would cause an unnecessary reduction in radioiodine uptake during therapy.
Conclusions
Administration of non-radioactive iodine two days after 131 Original in the absorbed energy dose in thyroid tissue, thereby improving therapeutic outcome without the necessity of administration of a higher or second radioiodine dose. Such a procedure will also minimize the whole-body exposure to radiation as well as reduce the total cost of therapy.
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